Journal article
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy.
Abstract
533
Background: Gene-expression profiling tests (e.g. Oncotype, Mammaprint, Prosignia, Breast Cancer Index and EndoPredict) are widely used in the care of patients with early-stage hormone positive breast cancer (node negative or 1-3 lymph nodes). However, these tests are resource intensive, and few studies have compared their value with either free and widely available clinico-pathologic risk calculators (e.g. PREDICT 2.1, …
Authors
Beltran-Bless A-A; Pond GR; Bayani J; Barker S; Spears M; Mallon E; Taylor KJ; Hasenburg A; Markopoulos C; Dirix LY
Journal
Journal of Clinical Oncology, Vol. 41, No. 16_suppl, pp. 533–533
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 1, 2023
DOI
10.1200/jco.2023.41.16_suppl.533
ISSN
0732-183X